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How Do Statins Work?
Changing Paradigms With Implications
for Statin Allocation*
Michael J. Blaha, MD, MPH, Seth S. Martin, MD
Baltimore, Maryland
There is now indisputable evidence that statins reduce
atherosclerotic cardiovascular disease events in a wide variety
of patient populations. As a result, up to 200 million people
take a daily statin worldwide, including over 30 million
people in the United States alone. Now that we have become
a statin civilization, perhaps it is time to ﬁgure out exactly
how these drugs work.See page 2382Meta-analyses have tied their favorable mechanism of
action to reduction in circulating low-density lipoprotein
cholesterol (LDL-C) (1), which is known to play a causal
role in atherosclerosis (2). The current National Cholesterol
Education Program Adult Treatment Panel III guidelines (3)
reﬂect the central belief in the serum LDL-C measurement,
recommending that the choice of who to treat and the
intensity of treatment should be inextricably tied to the
concentration of LDL-C in the bloodstream. Our mandate
has been to “lower the lipoprotein load” and “get to goal.”
However, a consistent stream of data suggests that there-
are favorable effects of statins independent of their inﬂuence
on circulating lipoprotein load. For example, statins have
been shown to reduce cardiovascular events in both primary
and secondary prevention at all levels of serum cholesterol,
including in those with so-called normal cholesterol levels
(baseline LDL-C <80 mg/dl) (4). When given as a loading
dose immediately before coronary revascularization, statins
appear to have a nearly immediate effect on lowering peri-
procedural myocardial infarction (5). As early as 4 months
following an acute coronary syndrome, statins reduce the
occurrence of unstable angina, suggesting a plaque-level
effect rather than cumulative exposure to the circulating*Editorials published in the Journal of the American College of Cardiology reﬂect the
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to disclose.lipoprotein load (6). Although controversial, statins may also
reduce atrial ﬁbrillation, venous thromboembolism, and
neurocognitive diseases such as Parkinson’s disease (7).
There are several potential explanations for these
apparently nonserum cholesterol mechanisms. For example,
statins have been shown to rapidly delipidate atheromas,
stripping plaques of their potentially unstable lipid core (8).
Statins also appear to reduce systemic inﬂammation, which
is important because subclinical inﬂammation is now
understood to create a proatherogenic milieu (9). They also
appear to reduce inﬂammation within the atherosclerotic
plaque itself, which might promote plaque stability (9).
Although much work still needs to be done, it is clear that
emerging research is taking us beyond the central focus on
cholesterol and the bloodstream and instead to the end-
effects of statins on peripheral tissue, including the athero-
sclerotic plaque itself.
These observations are fundamentally changing the way
we view statins. Historically, statins have been viewed as
exclusively lipid-lowering medications that should be
directed to patients with high serum lipid levels. A more
modern perspective paints statins as cardiovascular risk-
reducing medications with multiple possible mechanisms
of action.
Statin mechanism paradigms and their implications.
Our understanding of the mechanism of action of statins
will have a profound impact on the way we choose to allocate
this class of drugs and on the way we evaluate new classes
of lipid-modifying therapies. To simplify this important
discussion, we propose a taxonomy separating statin mecha-
nisms into 3 nonmutually exclusive paradigms. The question
is not which of these paradigms is correct, because they likely
all contribute. Rather, the question is which paradigm predo-
minates in which patient population over which time course.
PARADIGM 1: “LIPOPROTEIN LOAD HYPOTHESIS”. The lipo-
protein load hypothesis states that statins work primarily
by reducing the circulating burden of not only LDL-C, but
also all apolipoprotein B–containing lipoproteins (including
remnants), which by mass action kinetics leads to less age-
related build-up of lipid in the vessel wall. If the lipopro-
tein load hypothesis predominates, it would seem logical
to give statins to patients with high cholesterol as early
as possible in life to reduce the exposure to these dose-
dependent lipoprotein toxins. Within this framework, the
efﬁcacy of new classes of lipid-lowering therapies might be
best predicted by conducting detailed analysis of a new
drug’s effect on the lipid proﬁle.
PARADIGM 2: “SYSTEMIC INFLAMMATORY HYPOTHESIS”. This
hypothesis states that statins preferentially work by re-
ducing systemic subclinical inﬂammation, such as that seen in
the metabolic syndrome or in a condition like rheumatoid
arthritis, which promotes the propagation of early atheroscle-
rosis. If the systemic inﬂammatory hypothesis predominates,
statins should be given to patients with elevated levels of
serum inﬂammatory biomarkers, for example, high-sensitivity
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2393C-reactive protein (hsCRP), or evidence of extra-arterial
inﬂammation. Within this hypothesis, the efﬁcacy of new
antiatherosclerotic drugs might be best predicted by gauging
the effect on systemic inﬂammatory biomarkers.
PARADIGM 3: “PLAQUE MODULATION HYPOTHESIS”. This
hypothesis suggests that statins work predominantly by
changing the characteristics of early atherosclerotic plaque,
including delipidation, regression, reduction of plaque-level
inﬂammation, and plaque stabilization. If the plaque mod-
ulation hypothesis predominates, it would follow that statins
should be given to patients with subclinical atherosclerosis,
particularly those with so-called high-risk plaque features.
Within the framework of this hypothesis, the efﬁcacy of new
therapies might best be predicted by measuring the direct
impact of a new drug on the burden of atherosclerosis and
on the inﬂammatory activity of atherosclerotic plaque.
Measuring the nonlipid effects of statins. Modern
imaging techniques have made it possible to directly measure
some of the nonlipid effects of statins. For example, intra-
vascular ultrasound and coronary computed tomographic
angiography have helped us to understand the effect of
statins on total plaque burden and the quantity of lipid-rich,
low attenuation plaque. An important prior report by
Tawakol et al. (10) highlighted the possibility of using
ﬂuorodeoxyglucose (FDG)-positron emission tomography
(PET) to visualize plaque-level inﬂammation. In a feasibility
study of 83 patients (67 completed the study) with estab-
lished atherosclerosis or risk factors randomized to 10 mg
versus 80 mg of atorvastatin, the authors demonstrated
a dose-dependent reduction in FDG uptake within the
walls of the ascending aorta and carotid artery with in-
creasing dose of atorvastatin. This effect was present as early
as 4 weeks after initiation of atorvastatin. Importantly, the
reduction in plaque inﬂammation was largely independent
of reductions in LDL-C and hsCRP.
In this issue of the Journal, a new analysis from the same
FDG-PET study explores the dose-dependent effects of
atorvastatin on periodontal inﬂammation measured using
the same scans of the neck as those used for the carotid
artery (11). Periodontal disease is an emerging risk factor for
atherosclerotic cardiovascular disease, most likely because of
a systemic inﬂammatory response that could directly
promote inﬂammation within atherosclerotic plaques.
A total of 71 of the 83 patients completed the study, and
59 patients provided periodontal images for analysis. The
authors show that higher FDG-PET activity indeed iden-
tiﬁes more severe periodontal disease, as FDG uptake
correlated well with severity of disease by computed to-
mography. At 12 weeks, there was a reduction of activity in
patients randomized to 80 mg versus 10 mg of atorvastatin
(p ¼ 0.01). Importantly, those patients with the highest
levels of periodontal inﬂammation at baseline received the
greatest reduction with high-dose atorvastatin (p ¼ 0.004).
Intriguingly, the differences between the low- and high-dose
atorvastatin groups were already evident at just 4 weeksinto therapy. Similar to the prior carotid plaque inﬂamma-
tion analysis, reduction in the periodontal uptake was not
correlated with either LDL-C or hsCRP reduction. Re-
duction in FDG update did, however, correlate with
reduction in carotid artery FDG activity (r ¼ 0.61, r2¼ 0.37,
or 37% of the statistical variance explained), although this
study does not allow a causal inference between inﬂamma-
tion at these 2 sites.
Several limitations are worth mentioning. Of course,
sample size was small. Surprisingly, atorvastatin 10 mg
produced no change in periodontal FDG activitydall of the
reduction was seen in the atorvastatin 80 mg group. While
this could suggest a threshold effect, in general, conclusions
would be stronger if a true dose-response curve was
demonstrated. The authors attribute the lack of beneﬁt in
the atorvastatin 10-mg arm to a majority of patients taking
low-dose statins prior to enrollment. Given the short-term
follow-up of this study, one cannot determine the dura-
bility of the effect of high-dose statins on inﬂammation
past 12 weeks. Further, the clinical signiﬁcance of an
approximately 10% reduction in uptake on FDG-PET
imaging is entirely unknown.
The future of atherosclerosis treatment. Should new
lipid-lowering drugs undergo testing for so-called pleotropic
effects? It is interesting that dalcetrapib, despite markedly
increasing high-density lipoprotein cholesterol, did not
reduce arterial inﬂammation by FDG-PET (12). At
a minimum, we do not believe that it is safe to assume that
a drug that improves lipids (even, for example, such promis-
ing therapies as PCSK9 inhibitors) will be guaranteed to
proportionally reduce cardiovascular events at the same rate
as observed with statins.
Who should be treated with statins over what time
course is one of the most hotly debated questions in
modern medicine. While statins certainly reduce athero-
genic lipoproteins (see Paradigm 1), the 2 reports from this
intriguing FDG-PET feasibility study suggest that high-
dose statins also reduce extra-arterial inﬂammation (see
Paradigm 2) and inﬂammation within atherosclerotic pla-
que (see Paradigm 3). Ultimately, we hypothesize that the
relative importance of statin’s actionsdwithin the frame-
work of our proposed paradigmsdmay be population
dependent.
We applaud Subramanian et al. (11) for seeking a deeper
understanding of the way statins work. This hypothesis-
generating research has tremendous potential implications
for our philosophy toward statin allocation in primary pre-
vention and for future testing of new antiatherosclerotic
drugs.Reprint requests and correspondence: Dr. Michael J. Blaha,
Johns Hopkins Ciccarone Center for the Prevention of Heart
Disease, Carnegie 565A, JHH, 600 North Wolfe Street, Balti-
more, Maryland 21287. E-mail: Mblaha1@jhmi.edu.
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